Symbols / ENSC
ENSC Chart
About
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.38M |
| Enterprise Value | -225.28K | Income | -10.97M | Sales | 4.49M |
| Book/sh | 0.38 | Cash/sh | 0.47 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -0.17 | PEG | — |
| P/S | 0.31 | P/B | 1.01 | P/C | — |
| EV/EBITDA | — | EV/Sales | -0.05 | Quick Ratio | 0.73 |
| Current Ratio | 1.27 | Debt/Eq | 44.32 | LT Debt/Eq | — |
| EPS (ttm) | -6.35 | EPS next Y | -2.23 | EPS Growth | — |
| Revenue Growth | -85.60% | Earnings | 2025-11-14 16:00 | ROA | -109.79% |
| ROE | -294.39% | ROIC | — | Gross Margin | -135.44% |
| Oper. Margin | -7.59% | Profit Margin | -244.49% | Shs Outstand | 3.63M |
| Shs Float | 3.11M | Short Float | 5.56% | Short Ratio | 1.64 |
| Short Interest | — | 52W High | 5.72 | 52W Low | 0.31 |
| Beta | 1.15 | Avg Volume | 1.02M | Volume | 866.02K |
| Target Price | $16.45 | Recom | None | Prev Close | $0.39 |
| Price | $0.38 | Change | -2.86% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$16.45
Mean price target
2. Current target
$0.40
Latest analyst target
3. DCF / Fair value
$-15.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.40
Low
$16.45
High
$16.45
Mean
$16.45
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-09-25 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-07-03 | init | HC Wainwright & Co. | — → Buy | $9 |
- Drug developer Ensysce invited to 2026 pain and substance use research forums - Stock Titan Mon, 23 Feb 2026 13
- Should You Buy Ensysce Biosciences After Share Sale? - StocksToTrade ue, 09 Dec 2025 08
- Ensysce Flat on Review News - Baystreet.ca Wed, 28 Jan 2026 14
- Ensysce Biosciences files to sell 29.47M shares of common stock for holders - Intellectia AI Mon, 16 Feb 2026 21
- Inside a biotech developing pain pills with built-in overdose protection - Stock Titan Mon, 05 Jan 2026 08
- Ensysce Biosciences Narrows Loss in Q2 - Nasdaq Wed, 13 Aug 2025 07
- When Will Ensysce Biosciences, Inc. (NASDAQ:ENSC) Breakeven? - simplywall.st Wed, 12 Mar 2025 07
- Is Ensysce Biosciences a Hidden Gem? - timothysykes.com ue, 09 Dec 2025 08
- symbol__ Stock Quote Price and Forecast - CNN Fri, 19 Jan 2024 14
- Ensysce Biosciences (NASDAQ: ENSC) starts Phase 3 PF614 trial in abuse-deterrent opioid - Stock Titan ue, 09 Dec 2025 08
- When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)? - Yahoo Finance ue, 04 Feb 2025 08
- ENSC’s Future Brightens: A Swing to Watch? - StocksToTrade hu, 24 Apr 2025 07
- Ensysce Biosciences (ENSC) Stock Is Down 30% Today: What's Going On? - Sahm hu, 29 Aug 2024 07
- Opioid designed to stay inactive until swallowed hits Phase 3 milestone - Stock Titan Wed, 28 Jan 2026 08
- ENSC Stock Price and Chart — NASDAQ:ENSC - TradingView Fri, 02 Jul 2021 14
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -6.70M | -10.27M | -24.10M | -25.53M |
| TotalUnusualItems | 430.44K | 5.76M | -2.32M | |
| TotalUnusualItemsExcludingGoodwill | 430.44K | 5.76M | -2.32M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.99M | -10.61M | -24.17M | -29.08M |
| ReconciledDepreciation | 0.00 | 151.00 | ||
| EBITDA | -6.70M | -10.27M | -24.10M | -27.85M |
| EBIT | -6.70M | -10.27M | -24.10M | -27.85M |
| NetInterestIncome | -1.29M | -353.94K | -4.98M | -5.08M |
| InterestExpense | 1.29M | 353.94K | 109.53K | 1.30M |
| NormalizedIncome | -7.99M | -10.61M | -24.17M | -26.76M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.99M | -10.61M | -24.17M | -29.08M |
| TotalExpenses | 6.73M | 10.72M | 24.22M | 19.87M |
| TotalOperatingIncomeAsReported | -6.73M | -10.72M | -24.22M | -19.87M |
| DilutedAverageShares | 1.36M | 150.94K | 35.63K | 5.61K |
| BasicAverageShares | 1.36M | 150.94K | 35.63K | 5.61K |
| DilutedEPS | -11.45 | -70.40 | -2.09K | -5.33K |
| BasicEPS | -11.45 | -70.40 | -2.09K | -5.33K |
| DilutedNIAvailtoComStockholders | -7.99M | -10.63M | -25.09M | -29.89M |
| NetIncomeCommonStockholders | -7.99M | -10.63M | -25.09M | -29.89M |
| OtherunderPreferredStockDividend | 290.00 | 12.94K | 913.20K | 803.14K |
| NetIncome | -7.99M | -10.61M | -24.17M | -29.08M |
| MinorityInterests | 74.00 | 13.20K | 35.39K | 62.19K |
| NetIncomeIncludingNoncontrollingInterests | -7.99M | -10.63M | -24.21M | -29.15M |
| NetIncomeContinuousOperations | -7.99M | -10.63M | -24.21M | -29.15M |
| PretaxIncome | -7.99M | -10.63M | -24.21M | -29.15M |
| OtherIncomeExpense | 33.57K | 445.86K | 5.00M | -4.19M |
| OtherNonOperatingIncomeExpenses | 33.57K | 445.86K | 5.00M | -1.87M |
| SpecialIncomeCharges | 146.48K | 1.79M | -154.39K | |
| OtherSpecialCharges | -146.48K | -1.79M | 154.39K | |
| GainOnSaleOfSecurity | 283.96K | 5.76M | -2.32M | |
| NetNonOperatingInterestIncomeExpense | -1.29M | -353.94K | -4.98M | -5.08M |
| TotalOtherFinanceCost | 4.88M | 3.79M | ||
| InterestExpenseNonOperating | 1.29M | 353.94K | 109.53K | 1.30M |
| OperatingIncome | -6.73M | -10.72M | -24.22M | -19.87M |
| OperatingExpense | 6.73M | 10.72M | 24.22M | 19.87M |
| OtherOperatingExpenses | -5.21M | -2.23M | -2.52M | -3.53M |
| ResearchAndDevelopment | 7.22M | 7.59M | 19.84M | 4.69M |
| SellingGeneralAndAdministration | 4.72M | 5.36M | 6.91M | 18.71M |
| GeneralAndAdministrativeExpense | 4.72M | 5.36M | 6.91M | 18.71M |
| OtherGandA | 4.72M | 5.36M | 6.91M | 18.71M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 6.00 | 5.00 | ||
| OrdinarySharesNumber | 1.36M | 209.74K | 35.63K | 6.84K |
| ShareIssued | 1.36M | 209.74K | 35.63K | 6.84K |
| NetDebt | 1.26M | 4.92M | ||
| TotalDebt | 301.66K | 854.70K | 4.43M | 17.21M |
| TangibleBookValue | 3.71M | -322.86K | -3.71M | -7.88M |
| InvestedCapital | 4.01M | 531.84K | 692.31K | 9.31M |
| WorkingCapital | 3.14M | -1.04M | -4.17M | -819.07K |
| NetTangibleAssets | 3.71M | -322.86K | -3.71M | -7.88M |
| CapitalLeaseObligations | 0.00 | 27.32K | 24.87K | |
| CommonStockEquity | 3.71M | -322.86K | -3.71M | -7.88M |
| TotalCapitalization | 3.71M | -322.86K | -3.57M | -3.44M |
| TotalEquityGrossMinorityInterest | 3.38M | -651.27K | -4.03M | -8.16M |
| MinorityInterest | -328.48K | -328.41K | -315.21K | -279.81K |
| StockholdersEquity | 3.71M | -322.86K | -3.71M | -7.88M |
| RetainedEarnings | -129.54M | -121.56M | -110.93M | -85.85M |
| AdditionalPaidInCapital | 133.25M | 121.23M | 107.22M | 77.97M |
| CapitalStock | 136.00 | 21.00 | 53.00 | 124.00 |
| CommonStock | 136.00 | 21.00 | 53.00 | 124.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.22M | 3.36M | 9.91M | 24.58M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.10K | 26.39K | 450.49K | 8.09M |
| OtherNonCurrentLiabilities | 349.20K | |||
| DerivativeProductLiabilities | 10.10K | 26.39K | 310.35K | 3.30M |
| LongTermDebtAndCapitalLeaseObligation | 140.15K | 4.44M | ||
| LongTermDebt | 140.15K | 4.44M | ||
| CurrentLiabilities | 2.21M | 3.33M | 9.46M | 16.48M |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 301.66K | 854.70K | 4.29M | 12.77M |
| CurrentCapitalLeaseObligation | 0.00 | 27.32K | 24.87K | |
| CurrentDebt | 301.66K | 854.70K | 4.27M | 12.75M |
| OtherCurrentBorrowings | 301.66K | 854.70K | 4.27M | 12.75M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 0.00 | 1.34M | ||
| PayablesAndAccruedExpenses | 1.91M | 2.48M | 5.17M | 3.71M |
| CurrentAccruedExpenses | 548.46K | 542.26K | 2.23M | 3.41M |
| Payables | 1.36M | 1.94M | 2.94M | 301.10K |
| AccountsPayable | 1.36M | 1.94M | 2.94M | 301.10K |
| TotalAssets | 5.60M | 2.71M | 5.89M | 16.42M |
| TotalNonCurrentAssets | 252.55K | 419.22K | 585.88K | 754.76K |
| OtherNonCurrentAssets | 252.55K | 419.22K | 585.88K | 754.76K |
| NetPPE | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 5.34M | 2.29M | 5.30M | 15.66M |
| OtherCurrentAssets | 18.00K | 18.00K | 27.16K | 24.72K |
| PrepaidAssets | 1.70M | 1.05M | 1.85M | 2.93M |
| Receivables | 124.11K | 97.56K | 276.82K | 441.72K |
| OtherReceivables | 124.11K | 97.56K | 276.82K | 441.72K |
| CashCashEquivalentsAndShortTermInvestments | 3.50M | 1.12M | 3.15M | 12.26M |
| CashAndCashEquivalents | 3.50M | 1.12M | 3.15M | 12.26M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.50M | -10.78M | -17.89M | -8.24M |
| RepaymentOfDebt | -485.19K | -1.00M | -1.41M | -467.77K |
| IssuanceOfDebt | 0.00 | 1.61M | 7.53M | 14.38M |
| IssuanceOfCapitalStock | 1.67M | 9.05M | 3.78M | 6.63M |
| IncomeTaxPaidSupplementalData | 3.20K | 3.20K | 1.60K | 1.60K |
| EndCashPosition | 3.50M | 1.12M | 3.15M | 12.26M |
| BeginningCashPosition | 1.12M | 3.15M | 12.26M | 194.21K |
| ChangesInCash | 2.38M | -2.02M | -9.12M | 12.07M |
| FinancingCashFlow | 9.88M | 8.76M | 8.77M | 20.31M |
| CashFlowFromContinuingFinancingActivities | 9.88M | 8.76M | 8.77M | 20.31M |
| NetOtherFinancingCharges | -1.84M | -899.55K | -1.14M | -488.54K |
| ProceedsFromStockOptionExercised | 10.54M | 0.00 | 0.00 | 262.86K |
| NetCommonStockIssuance | 1.67M | 9.05M | 3.78M | 6.63M |
| CommonStockIssuance | 1.67M | 9.05M | 3.78M | 6.63M |
| NetIssuancePaymentsOfDebt | -485.19K | 605.43K | 6.13M | 13.91M |
| NetLongTermDebtIssuance | -485.19K | 605.43K | 6.13M | 13.91M |
| LongTermDebtPayments | -485.19K | -1.00M | -1.41M | -467.77K |
| LongTermDebtIssuance | 0.00 | 1.61M | 7.53M | 14.38M |
| InvestingCashFlow | 0.00 | 4.50K | 0.00 | |
| CashFlowFromContinuingInvestingActivities | 0.00 | 4.50K | 0.00 | |
| NetOtherInvestingChanges | 4.50K | |||
| OperatingCashFlow | -7.50M | -10.78M | -17.89M | -8.24M |
| CashFlowFromContinuingOperatingActivities | -7.50M | -10.78M | -17.89M | -8.24M |
| ChangeInWorkingCapital | -851.25K | -947.08K | 5.48M | -1.30M |
| ChangeInPayablesAndAccruedExpense | -572.73K | -2.52M | 3.66M | 754.25K |
| ChangeInAccruedExpense | 6.20K | -1.28M | 1.02M | 2.18M |
| ChangeInPayable | -578.93K | -1.23M | 2.64M | -1.42M |
| ChangeInAccountPayable | -578.93K | -1.23M | 2.64M | -1.42M |
| ChangeInPrepaidAssets | -251.97K | 1.39M | 1.65M | -1.62M |
| ChangeInReceivables | -26.55K | 179.26K | 164.90K | -441.72K |
| OtherNonCashItems | 1.24M | 344.65K | 8.29M | 7.33M |
| StockBasedCompensation | 110.72K | 879.16K | 1.07M | 121.76K |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | -146.48K | -1.79M | |
| DepreciationAmortizationDepletion | 0.00 | 151.00 | ||
| DepreciationAndAmortization | 0.00 | 151.00 | ||
| Depreciation | 0.00 | 151.00 | ||
| OperatingGainsLosses | -16.29K | -283.96K | -6.74M | 14.75M |
| GainLossOnInvestmentSecurities | -16.29K | -283.96K | -6.73M | 14.25M |
| NetIncomeFromContinuingOperations | -7.99M | -10.63M | -24.21M | -29.15M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ENSC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|